reviews on direct meds semaglutide glp 1 DirectMeds GLP-1 Reviews Patient Success Stories | DirectMeds

CMS Issues Coverage Guidance on GLP-1 Anti-Obesity Drugs: Implications for Health Plans Posted on April 5, 2024 CMS Issued Coverage Guidance on GLP-1 Anti-Obesity Drugs Requiring Considerations for Health Plans GLP-1s (glucagon-like peptide 1 agonist) came up in the news again after the Centers for Medicare and Medicaid Services (CMS) issued coverage guidance on GLP-1 anti-obesity drugs with expanded indications on March 20, 2024.* Since the inception of Medicare Part D, drugs used for weight loss have been excluded from basic coverage

Acute Kidney Injury: There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis, in patients treated with GLP-1 receptor agonists

Furthermore, the mediation analysis should be interpreted with caution, as it assumes no confounding factors beyond those included in the model (baseline body weight and stratification factors), which may not be the case, given that postrandomization events (GI AEs) are used in the analysis

Our 14-week medically supervised program, featuring a medication class of drugs called GLP-1 peptides, helps you effectively manage weight and achieve long-term success